NCT07235527Completed
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 54 (actual)
- First submitted
- 14 Nov 2025
- Start date
- 20 Nov 2025
- Primary completion date
- 20 Aug 2026
- Lead sponsor
- Saglik Bilimleri Universitesi
- Diseases
- Macular degeneration
- NCT number
- NCT07235527
What you commit to
- Study type: Observational
- Participants enrolled: 54
- From 20 Nov 2025 to the primary completion date, 20 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
- Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
Age
- Patients younger than 45 years or older than 90 years
Other
- Presence of uveitis
- Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
- Presence of hereditary retinal dystrophies
- Presence of optic atrophy
Who the study is looking for
- Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
- who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
- for whom intravitreal injection has already been clinically indicated
Age in the registry: 45 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prof. Dr. Cemil Taşcıoğlu City Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.